Chapter 13 - B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis

Abstract

Lupus nephritis (LN) is the most common and severe manifestation of systemic lupus erythematosus (SLE), affecting more than one-third of patients. LN is also an important contributor to morbidity and mortality in SLE patients. Despite advances in immunosuppressive therapies, outcomes have not significantly improved over the last two decades as only a minority of patients achieve the desired end point of complete renal response in clinical trials, underscoring a major therapeutic unmet need.